Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.